A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01).
Aaron James ScottAtrayee Basu MallickEfrat DotanSteven J CohenPhilip J GoldHoward S HochsterSomasundaram SubramaniamAfsaneh BarziGeorge S WattsPatrick J BlatchfordWells A MessersmithPublished in: Cancer research communications (2022)
Targeting angiogenesis through VEGF axis blockade provides incremental survival benefit in patients with mCRC. The hepatocyte growth factor/MET signal transduction pathway has been observed as a mechanism for acquired resistance. Dual inhibition of VEGF plus MET is an attractive therapeutic strategy. This phase II trial demonstrated clinical activity with cabozantinib, a multi-TKI targeting VEGFR2 and MET, in patients with refractory, mCRC.
Keyphrases
- vascular endothelial growth factor
- growth factor
- tyrosine kinase
- phase ii study
- metastatic colorectal cancer
- endothelial cells
- open label
- epidermal growth factor receptor
- cancer therapy
- metastatic renal cell carcinoma
- locally advanced
- placebo controlled
- drug delivery
- clinical trial
- advanced non small cell lung cancer
- randomized controlled trial
- squamous cell carcinoma